ReviewJournal of neural transmission (Vienna, Austria : 1996)2026
Motor and non-motor fluctuations in Parkinson's disease: the knowns and unknowns of current therapeutic approaches.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- On-demand therapies-emergency medication or daily routine?Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward.NeuroSci · 2026Review
- What's in a name? reframing advanced Parkinson's disease as a multidimensional state.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Current Trends in AI Gait Analysis for the Detection and Assessment of Parkinson's Disease Severity: Systematic Review and Meta-Analysis of Performance Using Logit Transformation.Healthcare (Basel, Switzerland) · 2026Review
- "ChatGPT knows my Parkinson's": Perspectives of people with Parkinson's disease on use of generative AI.Journal of Parkinson's disease · 2026Article
- Opicapone as Add-On Therapy to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: Clinical Improvement and Wearable Sensor-Based Gait Analysis.Brain sciences · 2026Article
- Real-world outcomes and early discontinuation of foslevodopa/foscarbidopa in Parkinson's disease.Journal of neurology · 2026Article
- Characterizing motor-cognitive associations in Parkinson's disease using digital assessments.Frontiers in aging neuroscience · 2026Article
- L-Dopa Comparably Improves Gait and Limb Movements in Parkinson's Disease: A Wearable Sensor Analysis.Biomedicines · 2025Article
- Initiating Apomorphine Therapy Without Antiemetic Pretreatment: Real-World Data From a Nurse-led Parkinson Disease Support Program.The Journal of neuroscience nursing : journal of the American Association of Neuroscience NursesArticle
- A dual timeline of safinamide effects in Parkinson's disease: mechanistic rationale and clinical implications.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegeneration in Parkinson's disease is chronically progressive, and no disease-modifying therapies have been approved so far. Fluctuations emerge in eventually all people with Parkinson's disease, and may lead to a high burden of motor and non-motor disability and significantly impair participation if they are inadequately treated. In recent years, the range of therapeutic options has expanded considerably. While different types of oral dopaminergic substances are initially applied to control fluctuations, additional routes of administration now encompass sublingual, inhalative, subcutaneous and transdermal applications. Different choices exist for on-demand and continuous pump therapies, as well as for deep brain stimulation. In this narrative review, we summarize the state of the art in the identification and treatment of motor and non-motor fluctuations in Parkinson's disease. Moreover, we discuss practical aspects of managing fluctuations, address yet unresolved questions and we offer insights into upcoming clinical developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.